Position in GILD
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$760,308,811
+$167,272,460 QoQ
Shares Held
6,017,958
+41.4% QoQ
Ownership
0.485%
of shares outstanding
% of Portfolio
0.68%
of 13F equity value
Holder Rank
#31
of 2,275 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 81%
Shared 0%
None 19%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Boston Partners holds $3,635,506,449 across 12 Drug Manufacturers - General names. GILD ranks #2 (20.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
4,784,316 | $1,203,925,277 | |
| 2 | GILD |
Gilead Sciences, Inc.
This page
|
6,017,958 | $760,308,811 | |
| 3 | AZN |
Astrazeneca PLC
|
3,177,627 | $602,541,630 | |
| 4 | JNJ |
Johnson & Johnson
|
1,113,805 | $282,873,054 | |
| 5 | BIIB |
Biogen Inc.
|
1,263,429 | $272,976,467 | |
| 6 | AMGN |
Amgen Inc
|
637,923 | $231,004,675 | |
| 7 | SNY |
Sanofi
|
3,844,844 | $164,021,044 | |
| 8 | MRK |
Merck & Co., Inc.
|
629,240 | $80,857,340 |
All Filings in GILD
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $760,308,811 | 6,017,958 | Shares | Defined | 2026-08-04 | |
| 2026-03-31 | $593,036,351 | 4,255,122 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $518,024,291 | 4,220,501 | Shares | Defined | 2026-02-13 | |
| 2020-09-30 | $281,574 | 4,456 | Shares | Defined | 2020-11-13 | |
| 2020-06-30 | $1,921,730 | 24,977 | Shares | Defined | 2020-08-12 | |
| 2020-03-31 | $75,605,684 | 1,011,312 | Shares | Defined | 2020-05-13 | |
| No filing history on record for this holder in this stock. | ||||||